본문 바로가기

University/Graduate

The cradle of student growth, a university that creates new values

Jeju National University’s School of Medicine has educated leading medical experts since it was first opened as the College of Medicine in 1998. The college was renamed to the Professional Graduate School of Medicine in 2008, and then again the current School of Medicine in 2019 to reflect the domestic and international educational environment as requested by students, faculty, and staff.

As the newest medical school approved in South Korea, the JNU School of Medicine has recently celebrated its 20th anniversary and entered a developing era. The school is located on Jeju Island, the nation’s largest island that has some of its most beautiful nature. The university’s facilities consist of the School of Medicine I and II, the first built inside the university’s campus, which has the pleasant environment, and the latter near the JNU Hospital, which is dubbed the hospital in the forest. The School of Medicine II has separate lecture rooms for each year of courses, along with the Clinical Skills Training Center, the Team-Based Learning Room, the Computer and Data Room, and the Men’s and Women’s Lounges. The university campus runs dormitory facilities for students from outside Jeju Island so they can stay focused on their schoolwork. There is also Sodeokheon near the JNU Hospital, which is a dormitory used only by the third- and fourth-year students of the School of Medicine who require clinical training. As the Korean Health Personal License Examination prioritizes performance test results, the school remodeled its Clinical Skills Training Center in 2019 to help students enhance their performance capacity and practice their skills in a facility that is similar to the national testing site. Students with financial issues are also entitled to receive various scholarships. Only 40 students a year are admitted to the course, which offers them the highest quality of education taught by passionate professors and staff members.

The School of Medicine has the vision of elevating the standards of medical education to lay the cornerstone for improving the healthcare conditions of the local community through supplying proficient healthcare professionals. Under this vision, the school has worked to educate medical experts with the greatest understanding of how to conduct research and to treat patients while fostering them to be good people, who can lead the local, national, and global healthcare industries.

The School of Medicine is evaluated by the Korean Institute of Medical Education and Evaluation. In 2015, the school won the highest rating medical education institution can receive.

To educate competent medical doctors and scientists from different backgrounds, the school offers not only regular lectures but also other forms of education, such as problem-based learning, team-based learning, case-based learning, and role play learning. Additionally, the school has strengthened its medical ethics course to help improve communication between doctors and patients. To this end, professors are also educated on the most up-to-date pedagogies. Throughout the historical changes in the school system, the faculty experienced more curricula and courses than any other medical school in the nation and have worked to enhance the school’s educational system.

By attending the School of Medicine, students can nurture their medical skills to properly treat patients, grow as individuals to provide the best care possible to their patients and family members, and become leaders who advance the local and national medical science industries.

Kang, Hee-Kyoung Professor

  • Major Pharmacology of Natural Products Anticancer Pharmacology Pharmacology of Trichogenic Agents
  • office School of Medicine, Room 221
  • Contact064-754-3846/+82-64-754-3846
  • E-mail pharmkhk@jejunu.ac.kr
  • Homepage  
Career and thesis
Career and thesis
Education 1984. 3 - 1988. 2 B.S., Department of Pharmacy, Seoul National University
1988. 3 - 1990. 2 M.S., Department of Pharmacy, Seoul National University
1990. 3 - 1995. 8 Ph.D., Department of Pharmacy, Seoul National University
Major career 1997. 7 - 1998. 9 Post-Doc., Department of Pharmacology, College of Medicine, Seoul National University
1998. 10 - 현재 Professor, Department of Pharmacology, Jeju National University School of Medicine
2002. 3 - 현재 Toxicology Professional, Korean Board of Toxicology
2004. 1 - 2005. 7 Visiting Professor, Department of Pharmacology, University of Cambridge, UK
2014. 8 - 2015. 7 Visiting Professor, Department of Pathology & Immunology, Washington University in St. Louis School of Medicine, MO, USA
main paper
● Kang JI, Kim SC, Kim MK, Boo HJ, Kim EJ, Im GJ, Kim YH, Hyun JW, Kang JH, Koh YS, Park DB, Yoo ES, Kang HK. Effects of dihydrotestosterone on rat dermal papilla cells in vitro. Eur J Pharmacol. 2015; 757:74-83.
● Kim EJ, Kang JI, Kwak JW, Jeon CH, Tung NH, Kim YH, Choi CH, Hyun JW, Koh YS, Yoo ES, Kang HK. The anticancer effect of (1S,2S,3E,7E,11E)-3,7,11, 15-cembratetraen-17,2-olide(LS-1) through the activation of TGF-β signaling in SNU-C5/5-FU, fluorouracil-resistant human colon cancer cells. Mar Drugs. 2015;13(3):1340-59.
● Boo HJ, Hong JY, Kim SC, Kang JI, Kim MK, Kim EJ, Hyun JW, Koh YS, Yoo ES, Kwon JM, Kang HK. The anticancer effect of fucoidan in PC-3 prostate cancer cells. Mar Drugs. 2013;11(8):2982-99.
● Kang JI, Kim EJ, Kim MK, Jeon YJ, Kang SM, Koh YS, Yoo ES, Kang HK. The promoting effect of Ishige sinicola on hair growth. Mar Drugs. 2013;11(6):1783-99.

+-

Yoo, Eun-Sook Professor

  • Major Pharmacology, Natural Product Pharmacology, Immunopharmacology
  • office Room M127, School of Medicine
  • Contact064-754-3847/+82-64-754-3847
  • E-mail eunsyoo@jejunu.ac.kr
  • Homepage  
Career and thesis
Career and thesis
Education Mar. 1989 ~ Feb. 1994. Ph.D. College of Pharmacy, Seoul National University
Mar. 1986 ~ Feb. 1988. M.S. College of Pharmacy, Seoul National University
Mar. 1982 ~ Feb. 1986. B.S. College of Pharmacy, Seoul National University
Major career 2000.09 ~ present Professor, Jeju National University School of Medicine
2008.08 ~ 2008.08 Visiting Professor, University of Utah
1994.03 ~ 2000.08 Chief Research Scientist, Research & Development Center, DaeWoong Pharmaceutical Co., Ltd.
main paper 1. Docosahexaenoic Acid Alleviates Atopic Dermatitis by Generating Tregs and IL-10/TGF-β-Modified Macrophages via a TGF-β-Dependent Mechanism, Journal of Investigative Dermatology, 2015, 13(4):2141-57

2. Diphlorethohydroxycarmalol inhibits interleukin-6 production by regulating NF-κB, STAT5 and SOCS1 in lipopolysaccharide-stimulated RAW264.7 cells, Marine Drugs, 2015, 135(6):1556-64

3. Quercetagetin inhibits macrophage-derived chemokine in HaCaT human keratinocytes via the regulation of signal transducer and activator of transcription 1, suppressor of cytokine signalling 1 and transforming growth factor-β1, British Journal of Dermatology, 2014, 171(3):512-23

4. Sargaquinoic acid isolated from Sargassum siliquastrum inhibits lipopolysaccharide-induced nitric oxide production in macrophages via modulation of nuclear factor-κB and c-Jun N-terminal kinase pathways, Immunopharmacology and Immunotoxicology, 2013; 35(1): 80?7

5. Fermented fish oil suppresses T helper 1/2 cell response in a mouse model of atopic dermatitis via generation of CD4+CD25+Foxp3+ T cells, BMC Immunology (2012) 13:44

6. Sargachromanol G regulates the expression of osteoclastogenic factors in human osteoblast-like MG-63 cells Food and Chemical Toxicology 50 (2012) 3273?279

7. Anti-inflammatory effect of methyl dehydrojasmonate (J2) is mediated by the NF-κB pathway J Mol Med (2011) 89:83?90

8. Two enone fatty acids isolated from Gracilaria verrucosa suppress the production of inflammatory mediators by down-regulating NF-kappaB and STAT1 activity in lipopolysaccharide-stimulated RAW 264.7 cells. Arch Pharm Res. 32(3):453-62 (2009)

+-

Jaeseong Oh Assistant Professor

  • Major Clinical pharmacology, Pharmacogenomics, Pharmacometrics, New drug development clinical trials, Personalized pharmacotherapy
  • office B209, Building 2 of Jeju National University's College of Medicine
  • Contact064-754-8129/+82-064-754-8129
  • E-mail jaeseong5@jejunu.ac.kr
  • Homepage  
Career and thesis
Career and thesis
Education ● Seoul National University College of Medicine, Seoul, Republic of Korea: M.D. (2011)
● Seoul National University Graduate School, Seoul, Republic of Korea: Ph.D. in Clinical Pharmacology (2018)
Major career ● 2023.9-Present Assistant Professor, Department of Pharmacology, Jeju National University College of Medicine
● 2020.3-2023.8 Clinical Professor, Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital
● 2018.9-2020.2 Research Professor, Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital
● 2015.9-2018.8 Technical Research Personnel, Seoul National University College of Medicine
● 2012.3-2015.8 Resident, Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital
main paper ● JI Kang, YK Choi, SC Han, JW Hyun, YS Koh, JS Oh, HJ Boo, ES Yoo, HK Kang. 5-Fluorouracil induces hair loss by inhibiting β-catenin signaling and angiogenesis. Chem Biol Interact. 2025 Feb 25:408:111416. doi: 10.1016/j.cbi.2025.111416.

● Joo Young Na, Juyeun Jeon, Ki Young Huh, Kyung-Sang Yu, Sangmi Lee, Jaehyun Eom, Jinhyung Ahn, Weon-Kyoo You, Jaeseong Oh. Population pharmacokinetic model of ABL001/CTX-009 (anti-VEGF/DLL4) in adult cancer patients with solid tumor. Cancer Sci. 2024 Dec;115(12):3943-3951.
doi: 10.1111/cas.16363.

● Yingxin Li, Joo Young Na, Yunting Zhu, Jaeseong Oh, Amy Zhao, In-Jin Jang, Lei Tang. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose riliprubart, an anti-C1s humanized monoclonal antibody in East-Asian adults: results from a Phase 1, randomized, open-label trial. Expert Opin Investig Drugs. 2024 Oct;33(10):1063-1074. doi: 10.1080/13543784.2024.2394186.

● Hyunwook Ryu, Hyun Chul Kim, Inseung Jeon, In-Jin Jang, Joo-Youn Cho , Kyung Tae Kim, Jaeseong Oh. Pharmacokinetic Interactions Between the Fixed-Dose Combination of Ezetimibe/Rosuvastatin 10/20 Mg and the Fixed-Dose Combination of Telmisartan/Amlodipine 80/5 Mg in Healthy Subjects. Drug Des Devel Ther. 2024 Jul 1:18:2641-2652. doi: 10.2147/DDDT.S465652.

● Xu Jiang, Kyung-Sang Yu, Dong Hyuk Nam, Jaeseong Oh. A Population Pharmacokinetic Study to Compare a Novel Empagliflozin L-Proline Formulation with Its Conventional Formulation in Healthy Subjects. Pharmaceuticals(Basel). 2024 Apr 18;17(4):522. doi: 10.3390/ph17040522.

● Heejae Won, Deok Yong Yoon, Sangmi Lee, Joo-Youn Cho, Jaeseong Oh, In-Jin Jang, Sang-Ku Yoo, Kyung-Sang Yu. Effects of meal type on the bioavailability of vutiglabridin, a novel anti-obesity agent, in healthy subjects. Clin Transl Sci. 2024 Mar;17(3):e13744. doi: 10.1111/cts.13744.

● Woo Kyung Chung, Ki Young Huh, Jiyeon Park, Jaeseong Oh, Kyung-Sang Yu. Establishment of Advanced Regulatory Innovation for Clinical Trials Transformation (ARICTT): a multi-stakeholder public-private partnership-based organization to accelerate the transformation of clinical trials. Transl Clin Pharmacol. 2024 Mar;32(1):30-40. doi: 10.12793/tcp.2024.32.e1.

● Juyoung Khwarg, Soyoung Lee, In-Jin Jang, Won-Ho Kang, Hye Jung Lee, Kyu Yeon Kim , Ki-Sun Jeong, Chongho Won, Youn Woong Choi, Dae Chul Ha, RaeHoon Jung , Min-Gu Han, Won Tae Jung, Kyu-Yeol Nam, YeSeul Kim, Kyung-Sang Yu, Jaeseong Oh. Pharmacokinetic Comparison Between a Fixed-Dose Combination of Atorvastatin/Omega-3-Acid Ethyl Esters and the Corresponding Loose Combination in Healthy Korean Male Subjects. Drug Des Devel The. 2024 Feb 8:18:395-406. doi: 10.2147/DDDT.S435885.

● Byungwook Kim, Joo-Youn Cho, Ildae Song, Jaeseong Oh. Pharmacogenetic Analysis of an 8-Year Old Girl with Reye Syndrome Associated with Use of Naproxen. Am J Case Rep. 2024 Feb 5:25:e942242. doi: 10.12659/AJCR.942242.

● Hyun Chul Kim, Eunsol Yang, Soyoung Lee, Jaeseong Oh, Myongjae Lee, ChaeEun Lee, Kyoung Soo Ha, Won Sik Lee, In-Jin Jang, Kyung-Sang Yu. Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects. Invest New Drugs. 2024 Feb;42(1):80-88. doi: 10.1007/s10637-023-01405-z.

● Lee H, Hwang S, Jang IJ, Chung JY, Oh J. Adaptive design clinical trials: current status by disease and trial phase in various perspectives. Transl Clin Pharmacol. 2023 Dec;31(4):202-216. doi: 10.12793/tcp.2023.31.e21.

● Ki Young Huh, Woo Kyung Chung, Ji yeon Park, SeungHwan Lee , Min-Gul Kim, Jaeseong Oh, Kyung-Sang Yu. Feasibility study for a fully decentralized clinical trial in participants with functional constipation symptoms. Clin Transl Sci.2023 Nov;16(11):2177-2188. doi: 10.1111/cts.13617.

● Soyoung Lee, Kyung Taek Hong, In-Jin Jang, Kyung-Sang Yu, Hyoung Jin Kang, Jaeseong Oh. Semimechanistic pharmacokinetic–pharmacodynamic model of tripegfilgrastim for pediatric patients after chemotherapy. CPT Pharmacometrics Syst Pharmacol. 2023 Sep;12(9):1319-1334. doi: 10.1002/psp4.13012.

● Park MY, Bae S, Heo JA, Park M, Kim Y, Han J, Jang IJ, Yu KS, Oh J. Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl-tRNA synthetase inhibitor, in healthy subjects. Clin Transl Sci. 2023 Apr 24.

● Kim BR, Lim L, Choi Y, Yi NJ, Lee KW, Suh KS, Yu KS, Sohn JY, Jeong R, Oh J, Ryu HG. Continuous versus intermittent infusion of human antithrombin III concentrate in the immediate postoperative period after liver transplantation. Clin Transl Sci. 2023 Apr 10.

● Chung WK, Hwang I, Kim B, Jung J, Yu KS, Jang IJ, Oh J. Pharmacokinetics, safety and tolerability of valbenazine in Korean CYP2D6 normal and intermediate metabolizers. Clin Transl Sci. 2023 Mar;16(3):512-523.

● Oh J, Yang E, Jang IJ, Lee H, Yoo H, Chung JY, Lee S, Oh J. Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects. Pharmaceutics. 2023 Feb 7;15(2):549.

● Hwang S, Lee S, Kim E, Hwang I, Cho JY, Chung JY, Jang IJ, Oh J. The pharmacokinetic, safety, and tolerability profiles of eslicarbazepine acetate are comparable between Korean and White subjects. Clin Transl Sci. 2022 Sep;15(9):2116-2126.

● Park Y, Na JY, Cho JY, Oh J, Rhee SJ. Key Considerations for Phase 2 or 3 Clinical Study Design of Anti-Inflammatory Agent for COVID-19 Treatment. Front Pharmacol. 2022 Jun 2;13:842836.

● Lee S, Hong KT, Moon SJ, Choi JY, Hong CR, Shin HY, Cho JY, Jang IJ, Yu KS, OhJ, Kang HJ. Pharmacokinetic and Pharmacodynamic Characteristics of Tripegfilgrastim, a Pegylated G-CSF, in Pediatric Patients with Solid Tumors. Clin Pharmacol Ther. 2022 Jan;111(1):293-301.

● Yoo H, Chun Ji S, Cho JY, Kim SH, Yoon JG, Goo Lee M, Yu KS, Jang IJ, OhJ. A pilot study to investigate the utility of NAT2 genotype-guided isoniazid monotherapy regimens in NAT2 slow acetylators. Pharmacogenet Genomics. 2021 Apr 1;31(3):68-73.

● Jeon I, OhJ, Kwon YK, Yoon SH, Cho JY, Jang IJ, Yu KS, Lee S. Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP®) Biosimilar, to Those of NESP® After a Single Subcutaneous or Intravenous Administration to Healthy Subjects. Drug Des Devel Ther. 2021 Apr 28;15:1735-1747.

● Lee SW, OhJ, Kim AH, Ji SC, Park SI, Yoon SH, Chung JY, Yu KS, Jang IJ, Lee S. Oral absorption of voriconazole is affected by SLCO2B1 c.*396T>C genetic polymorphism in CYP2C19 poor metabolizers. Pharmacogenomics J. 2020 Dec;20(6):792-800.

● Ngo L, OhJ, Kim A, Back HM, Kang WH, Chae JW, Yun HY, Lee H. Development of a Pharmacokinetic Model Describing Neonatal Fc Receptor-Mediated Recycling of HL2351, a Novel Hybrid Fc-Fused Interleukin-1 Receptor Antagonist, to Optimize Dosage Regimen. CPT Pharmacometrics Syst Pharmacol. 2020 Oct;9(10):584-595.

● Oh J, Huh KY, Cho YG, Cha JE, Kim SJ, Yoon SH, Park SS, Yoon H, Lee J, Lee H. Safety, tolerability and pharmacokinetics and pharmacodynamics of HL2351, a novel hybrid fc-fused interleukin-1 receptor antagonist, in healthy subjects: A first-in-human study. Br J Clin Pharmacol. 2020 Feb;86(2):372-379.

● Kim BR, OhJ, Yu KS, Ryu HG. Pharmacokinetics of human antithrombin III concentrate in the immediate postoperative period after liver transplantation. Br J Clin Pharmacol. 2020;86(5):923-932. doi:10.1111/bcp.14200

+-


TOP